Q-omics provides the consensus-scored SORCS3 profile across patient tissues and cancer cell-line models. SORCS3 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, SORCS3 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, SORCS3 RNA expression shows 12,406 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LUAD, KICH, and TGCT as cancer lineages where SORCS3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SORCS3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SORCS3 survival associations across molecular data types. SORCS3 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (11) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SORCS3 RNA expression–survival associations across cancer types. High SORCS3 expression shows unfavorable associations in LUAD, LIHC and COAD, but favorable associations in UVM, ACC and LGG. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for SORCS3 RNA expression.
This table summarizes SORCS3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in KICH for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SORCS3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SORCS3 shows lower tumor expression in KICH, COAD, STAD, UCEC and KIRP and higher tumor expression in KIRC. The KICH box plot shows higher SORCS3 RNA expression in normal versus tumor tissue (log2 FC = −0.935, t-test p < 0.001).
This table shows molecular features associated with SORCS3 in patient tissues and cancer cell lines. In patient samples, SORCS3 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, SORCS3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and STOMACH.
